All In Biotech

Drug Trial Radar · NCT00076232

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals

Last checked: Nov 19, 2026Latest source record: Dec 30, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,682 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,682

Planned (sponsor's estimate)

Start

Apr 2005

Primary completion

Jun 2007

Study completion Nov 2007

Sponsor

Sponsor type
NIH
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
First posted
Jan 16, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV. This study will test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes drug, in preventing HIV infection in HSV-2 infected women who sleep with men (WSM) and men who sleep with men (MSM). Study hypothesis: Given that genital herpes is a significant risk factor to HIV acquisition, twice-daily HSV-2 suppressive therapy - 400 mg of acyclovir - will prevent HIV infection among high risk, HSV-2 seropositive WSM and MSM.

Conditions

  • HIV Infections
  • HIV Seronegativity
  • Herpes Genitalis

Interventions

  • AcyclovirDrug

    400 mg tablet taken orally twice daily

  • Acyclovir placeboDrug

    Oral tablet taken twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serologically confirmed HIV infectionTime frame: Throughout study

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • San Francisco Department of Public Health, AIDS Office, Research Section

    San Francisco, California

  • New York Blood Center

    New York, New York

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.